Iloprost inahalation Solution
Form: Inhalation Solution (Nebulizer)
Strength: 10 mcg/mL
Reference Brands: Ventavis®(EU & US)
Category: Orphan Drugs
Iloprost inhalation solution, marketed as Ventavis®, is approved in the US and EU for pulmonary arterial hypertension (PAH). Regulatory dossiers include detailed clinical trials, manufacturing standards, and safety data submitted to FDA and EMA, supporting its approval. The inhalation therapy delivers prostacyclin directly to the lungs, improving exercise capacity and symptoms. The product is supplied in vials of 20 mcg/mL for nebulization, with dosing tailored to individual patient needs. For comprehensive insights on regulatory submissions, dossier requirements, and market approvals, visit PharmaTradz, your trusted source for pharmaceutical regulatory updates and industry insights.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Galsulfase IV
Strength: 1mg/ml
Form: Lyophilized powder for IV
Reference Brands: Vimizim®(US & EU)
View Details Get Enquiry
Alglucosidase Alfa IV
Strength: 50 mg/vial
Form: Lyophilized powder
Reference Brands: Lumizyme®(US & EU)
View Details Get Enquiry
Nitisinone tablets
Strength: 2 mg and 5 mg
Form: Tablets
Reference Brands: Orfadin®
View Details Get Enquiry
Treprostinil IV or SC
Strength: 2 mg (0.1 mg/mL), 4 mg (0.2 mg/mL), 8 mg (0.4 mg/mL), 20 mg (1 mg/mL), 50 mg (2.5 mg/mL), 100 mg (5 mg/mL), 200 mg (10 mg/mL), or 400 mg (20 mg/mL)
Form: SC or Intravenous (IV)
Reference Brands: Remodulin®(US & EU)
View Details Get Enquiry